Ascites: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Robert Badgett
mNo edit summary
 
(15 intermediate revisions by 4 users not shown)
Line 1: Line 1:
{{subpages}}
{{subpages}}
'''Ascites''', also called '''hydroperitoneum''' or '''dropsy of the peritoneum''', is the accumulation of [[serous]] fluids in the space between the tissues and organs of the abdominal ([[peritoneal]]) cavity.  It can be a sign of serious health problems. It is often associated with [[cirrhosis]] or [[hepatitis]], but may occur due to [[constrictive pericarditis]], [[congestive heart failure]], [[liver cancer|liver]] and [[ovarian cancer]], [[pancreatitis]], [[nephrotic syndrome]], protein-losing [[enteropathy]] or [[portal vein]] [[thrombosis]].  The fluids can build up enough to cause pain and shortness of breath due to pressure on the diaphram.<ref>The National Institutes of Health [http://www.nlm.nih.gov/medlineplus/ency/article/000286.htm]</ref>
{{TOC|right}}
'''Ascites''', also called '''hydroperitoneum''' or '''dropsy of the peritoneum''', is the accumulation of [[serous]] fluids in the space between the tissues and organs of the abdominal ([[peritoneal]]) cavity.  It can be a sign of serious health problems. It is often associated with [[cirrhosis]] or [[hepatitis]], but may occur due to [[constrictive pericarditis]], [[congestive heart failure]], [[liver cancer|liver]] and [[ovarian cancer]], [[pancreatitis]], [[nephrotic syndrome]], protein-losing [[enteropathy]] or [[portal vein]] [[thrombosis]].  The fluids can build up enough to cause pain and shortness of breath due to pressure on the diaphram.<ref>Anonymous. [http://www.nlm.nih.gov/medlineplus/ency/article/000286.htm Ascites]. [[National Library of Medicine]]</ref>


==Classification==
==Classification==
Line 21: Line 22:
===Mixed causes===
===Mixed causes===
Among patients with cirrhosis, 5%<ref name="pmid1616215">{{cite journal| author=Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, McHutchison JG| title=The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. | journal=Ann Intern Med | year= 1992 | volume= 117 | issue= 3 | pages= 215-20 | pmid=1616215  
Among patients with cirrhosis, 5%<ref name="pmid1616215">{{cite journal| author=Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, McHutchison JG| title=The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. | journal=Ann Intern Med | year= 1992 | volume= 117 | issue= 3 | pages= 215-20 | pmid=1616215  
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=1616215 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref> will have an additional etiology present. The most common second etiologies are tuberculous peritonitis and malignancy.<ref name="pmid1616215"/>
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=1616215 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref> will have an additional etiology present. The most common second etiologies are [[spontaneous bacterial peritonitis]], tuberculous peritonitis, and malignancy.<ref name="pmid1616215"/>
Among patients who have
Among patients who have malignancy, most have abnormal imaging.<ref name="pmid19491852">{{cite journal| author=Khandwalla HE, Fasakin Y, El-Serag HB| title=The utility of evaluating low serum albumin gradient ascites in patients with cirrhosis. | journal=Am J Gastroenterol | year= 2009 | volume= 104 | issue= 6 | pages= 1401-5 | pmid=19491852
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=19491852 | doi=10.1038/ajg.2009.117 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref>


==Diagnosis==
==Diagnosis==
Line 44: Line 46:
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=18334692 | doi=10.1001/jama.299.10.1166 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref>
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=18334692 | doi=10.1001/jama.299.10.1166 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref>


The serum-ascites albumin gradient (SAAG) is usually above 1.1 g/dl; however, even lower values usually are due to portal hypertension.<ref name="pmid19491852">{{cite journal |author=Khandwalla HE, Fasakin Y, El-Serag HB |title=The utility of evaluating low serum albumin gradient ascites in patients with cirrhosis |journal=Am. J. Gastroenterol. |volume=104 |issue=6 |pages=1401–5 |year=2009 |month=June |pmid=19491852 |doi=10.1038/ajg.2009.117 |url=http://dx.doi.org/10.1038/ajg.2009.117 |issn=}}</ref>
The serum-ascites albumin gradient (SAAG) is usually above 1.1 g/dl; however, even lower values usually are due to portal hypertension.<ref name="pmid19491852"></ref>
 
===Testing for tuberculosis===
Among patients with ascites, some patients will have underlying [[tuberculosis]].<ref name="pmid1616215">{{cite journal| author=Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, McHutchison JG| title=The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. | journal=Ann Intern Med | year= 1992 | volume= 117 | issue= 3 | pages= 215-20 | pmid=1616215
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=1616215 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref> will have an additional etiology present. The most common second etiologies are [[spontaneous bacterial peritonitis]], tuberculous peritonitis, and malignancy.<ref name="pmid1616215"/>  Some of these patients will have a positive [[purified protein derivative]] (PPD) test.
 
===Imaging===
Among patients with ascites, some patients will have underlying malignancy.<ref name="pmid1616215">{{cite journal| author=Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, McHutchison JG| title=The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. | journal=Ann Intern Med | year= 1992 | volume= 117 | issue= 3 | pages= 215-20 | pmid=1616215
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=1616215 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref> will have an additional etiology present. The most common second etiologies are [[spontaneous bacterial peritonitis]], tuberculous peritonitis, and malignancy.<ref name="pmid1616215"/> Most patients with malignancy will have abnormal imaging.<ref name="pmid19491852">{{cite journal| author=Khandwalla HE, Fasakin Y, El-Serag HB| title=The utility of evaluating low serum albumin gradient ascites in patients with cirrhosis. | journal=Am J Gastroenterol | year= 2009 | volume= 104 | issue= 6 | pages= 1401-5 | pmid=19491852
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=19491852 | doi=10.1038/ajg.2009.117 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref>


==Treatment==
==Treatment==
Line 53: Line 64:


===Diuretics===
===Diuretics===
Since salt restriction is the basic concept in treatment, and [[aldosterone]] is one of the hormones that acts to increase salt retention, a medication that counteracts aldosterone should be sought. [[Spironolactone]] (or other distal-tubule diuretics such as [[triamterene]] or [[amiloride]]) is the drug of choice since they block the aldosterone receptor in the collecting tubule. This choice has been confirmed in a [[randomized controlled trial]].<ref name="pmid7035545">{{cite journal |author=Fogel MR, Sawhney VK, Neal EA, Miller RG, Knauer CM, Gregory PB |title=Diuresis in the ascitic patient: a randomized controlled trial of three regimens |journal=J. Clin. Gastroenterol. |volume=3 Suppl 1 |issue= |pages=73-80 |year=1981 |pmid=7035545 |doi=}}</ref> Diuretics for ascites should be dosed once per day.<ref name="pmid8277955">{{cite journal |author=Runyon BA |title=Care of patients with ascites |journal=N. Engl. J. Med. |volume=330 |issue=5 |pages=337-42 |year=1994 |pmid=8277955 |doi=}}</ref> Generally, the starting dose is oral spironolactone 100 mg/day (max 400 mg/day).
Since salt restriction is important in treatment, and [[aldosterone]] is one of the hormones that acts to increase salt retention, a medication that counteracts aldosterone should be beneficial. [[Spironolactone]] (or other distal-tubule diuretics such as [[triamterene]] or [[amiloride]]) block the aldosterone receptor in the collecting tubule. Their benefit was shown in a [[randomized controlled trial]].<ref name="pmid7035545">{{cite journal |author=Fogel MR, Sawhney VK, Neal EA, Miller RG, Knauer CM, Gregory PB |title=Diuresis in the ascitic patient: a randomized controlled trial of three regimens |journal=J. Clin. Gastroenterol. |volume=3 Suppl 1 |issue= |pages=73-80 |year=1981 |pmid=7035545 |doi=}}</ref>
40% of patients will respond to spironolactone.<ref name="pmid1860680"/> For nonresponders, a [[loop diuretic]] may also be added and generally, [[furosemide]] is added at a dose of 40 mg/day (max 160 mg/day), or alternatively ([[bumetanide]] or [[torasemide]]). The ratio of 100:40 reduces risks of potassium imbalance.<ref name="pmid8277955"/> Serum [[potassium]] level and renal function should be monitored closely while on these medications.<ref name="pmid15084697">{{cite journal |author=Ginès P, Cárdenas A, Arroyo V, Rodés J |title=Management of cirrhosis and ascites |journal=N. Engl. J. Med. |volume=350 |issue=16 |pages=1646-54 |year=2004 |pmid=15084697 |doi=10.1056/NEJMra035021}}</ref>
 
Diuretics for ascites should be dosed once per day.<ref name="pmid8277955">{{cite journal |author=Runyon BA |title=Care of patients with ascites |journal=N. Engl. J. Med. |volume=330 |issue=5 |pages=337-42 |year=1994 |pmid=8277955 |doi=}}</ref> Generally, the starting dose is oral spironolactone 100 mg/day (max 400 mg/day). 40% of patients will respond to spironolactone.<ref name="pmid1860680"></ref> For nonresponders, a [[loop diuretic]] may also be added and generally, [[furosemide]] is added at a dose of 40 mg/day (max 160 mg/day), or alternatively ([[bumetanide]] or [[torasemide]]). The ratio of 100:40 reduces risks of potassium imbalance.<ref name="pmid8277955"/> Serum [[potassium]] level and renal function should be monitored closely while on these medications.<ref name="pmid15084697"></ref>
 
A preliminary randomized controlled trial suggests that  hypertonic saline solution combined with high-dose [[furosemide]] may be an effective alternative to repeated paracentesis for hospitalized patients.<ref name="pmid19438847">{{cite journal| author=Licata G, Tuttolomondo A, Licata A, Parrinello G, Di Raimondo D, Di Sciacca R et al.| title=Clinical Trial: High-dose furosemide plus small-volume hypertonic saline solutions vs. repeated paracentesis as treatment of refractory ascites. | journal=Aliment Pharmacol Ther | year= 2009 | volume= 30 | issue= 3 | pages= 227-35 | pmid=19438847
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=19438847 | doi=10.1111/j.1365-2036.2009.04040.x }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref>
 
;Monitoring diuresis
;Monitoring diuresis
Diuresis can be monitored by weighing the patient daily. The goal is weight loss of no more than 1.0 kg/day for patients with both ascites and [[peripheral edema]] and no more than 0.5 kg/day for patients with ascites alone.<ref name="pmid4910836">{{cite journal |author=Shear L, Ching S, Gabuzda GJ |title=Compartmentalization of ascites and edema in patients with hepatic cirrhosis |journal=N. Engl. J. Med. |volume=282 |issue=25 |pages=1391-6 |year=1970 |pmid=4910836 |doi=}}</ref>
Diuresis can be monitored by weighing the patient daily. The goal is weight loss of no more than 1.0 kg/day for patients with both ascites and [[peripheral edema]] and no more than 0.5 kg/day for patients with ascites alone.<ref name="pmid4910836">{{cite journal |author=Shear L, Ching S, Gabuzda GJ |title=Compartmentalization of ascites and edema in patients with hepatic cirrhosis |journal=N. Engl. J. Med. |volume=282 |issue=25 |pages=1391-6 |year=1970 |pmid=4910836 |doi=}}</ref>
If daily weights cannot be obtained, diuretics can also be guided by the urinary sodium concentration. Dosage is increased until a negative sodium balance occurs.<ref name="pmid8277955"/>  A random urine sodium-to-potassium ratio of > 1 is 90% [[sensitivity (tests)|sensitive]] in predicting negative balance (> 78-mmol/day sodium excretion).<ref name="Runyon1996">Runyon BA, Heck M. Utility of 24-hour urine sodium collection and urine Na/K ratios in the management of patients with cirrhosis and ascites [abstract]. Hepatology. 1996;24:571A.</ref>
If daily weights cannot be obtained, diuretics can also be guided by the urinary sodium concentration. Dosage is increased until a negative sodium balance occurs.<ref name="pmid8277955"/>  A random urine sodium-to-potassium ratio of > 1 is 90% [[sensitivity (tests)|sensitive]] in predicting negative balance (> 78-mmol/day sodium excretion).<ref name="Runyon1996">Runyon BA, Heck M. Utility of 24-hour urine sodium collection and urine Na/K ratios in the management of patients with cirrhosis and ascites [abstract]. Hepatology. 1996;24:571A.</ref>
;Diuretic resistance
;Diuretic resistance
Diuretic resistance can be predicted by giving 80 mg intravenous furosemide after 3 days without diuretics and on an 80 mEq sodium/day diet. The urinary sodium excretion over 8 hours < 50 mEq/8 hours predicts resistance.<ref name="pmid11124817">{{cite journal |author=Spahr L, Villeneuve JP, Tran HK, Pomier-Layrargues G |title=Furosemide-induced natriuresis as a test to identify cirrhotic patients with refractory ascites |journal=Hepatology |volume=33 |issue=1 |pages=28-31 |year=2001 |pmid=11124817 |doi=10.1053/jhep.2001.20646}}</ref>
Diuretic resistance can be predicted by giving 80 mg intravenous furosemide after 3 days without diuretics and on an 80 mEq sodium/day diet. The urinary sodium excretion over 8 hours < 50 mEq/8 hours predicts resistance.<ref name="pmid11124817">{{cite journal |author=Spahr L, Villeneuve JP, Tran HK, Pomier-Layrargues G |title=Furosemide-induced natriuresis as a test to identify cirrhotic patients with refractory ascites |journal=Hepatology |volume=33 |issue=1 |pages=28-31 |year=2001 |pmid=11124817 |doi=10.1053/jhep.2001.20646}}</ref>
Line 66: Line 83:
===Paracentesis===
===Paracentesis===
In those with severe (tense) ascites, therapeutic [[paracentesis]] may be needed in addition to medical treatments listed above.<ref name="pmid3297907"/><ref name="pmid3655306"/> As this may deplete [[serum albumin]] levels in the blood, albumin is generally administered intravenously in proportion to the amount of ascites removed.
In those with severe (tense) ascites, therapeutic [[paracentesis]] may be needed in addition to medical treatments listed above.<ref name="pmid3297907"/><ref name="pmid3655306"/> As this may deplete [[serum albumin]] levels in the blood, albumin is generally administered intravenously in proportion to the amount of ascites removed.
===Shunting===
In patients with resistant ascites, shunts mayhelp. Options are [[portacaval shunt]], [[peritoneovenous shunt]], and the [[transjugular intrahepatic portosystemic shunt]] (TIPSS). However, none of these shunts has been shown to extend life expectancy.<!-- and are considered to be bridges to [[liver transplantation]].-->
Peritoneovenous shunt can speed resolution of ascites and delay its recurrence.<ref name="pmid2586565">{{cite journal| author=Stanley MM, Ochi S, Lee KK, Nemchausky BA, Greenlee HB, Allen JI et al.| title=Peritoneovenous shunting as compared with medical treatment in patients with alcoholic cirrhosis and massive ascites. Veterans Administration Cooperative Study on Treatment of Alcoholic Cirrhosis with Ascites. | journal=N Engl J Med | year= 1989 | volume= 321 | issue= 24 | pages= 1632-8 | pmid=2586565
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=2586565 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref> PV shunt has a restricted role, in part due to a 40% rate of obstruction over one year.<ref name="pmid8550036">{{cite journal| author=Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G et al.| title=Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. | journal=Hepatology | year= 1996 | volume= 23 | issue= 1 | pages= 164-76 | pmid=8550036
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=8550036 | doi=10.1002/hep.510230122 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref>
TIPSS was better than peritoneovenous shunt in a [[randomized controlled trial]].<ref name="pmid15166968">{{cite journal| author=Rosemurgy AS, Zervos EE, Clark WC, Thometz DP, Black TJ, Zwiebel BR et al.| title=TIPS versus peritoneovenous shunt in the treatment of medically intractable ascites: a prospective randomized trial. | journal=Ann Surg | year= 2004 | volume= 239 | issue= 6 | pages= 883-9; discussion 889-91 | pmid=15166968
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=15166968 | pmc=PMC1356297 }} <!--Formatted by http://sumsearch.uthscsa.edu/cite/--></ref>


===Liver transplantation===
===Liver transplantation===
Ascites that is refractory to medical therapy is considered an indication for [[liver transplantation]]. In the United States, the [[MELD Score]] ([http://www.unos.org/resources/meldPeldCalculator.asp online calculator])<ref name="pmid2682175">{{cite journal |author=Cosby RL, Yee B, Schrier RW |title=New classification with prognostic value in cirrhotic patients |journal=Mineral and electrolyte metabolism |volume=15 |issue=5 |pages=261-6 |year=1989 |pmid=2682175 |doi=}}</ref> is used to prioritize patients for transplantation.
Ascites that is refractory to medical therapy is considered an indication for [[liver transplantation]]. In the United States, the [[MELD Score]] ([http://www.unos.org/resources/meldPeldCalculator.asp online calculator])<ref name="pmid2682175">{{cite journal |author=Cosby RL, Yee B, Schrier RW |title=New classification with prognostic value in cirrhotic patients |journal=Mineral and electrolyte metabolism |volume=15 |issue=5 |pages=261-6 |year=1989 |pmid=2682175 |doi=}}</ref> is used to prioritize patients for transplantation.
===Shunting===
In a minority of the patient with advanced cirrhosis that have recurrent ascites, shunts may be used. Typical shunts used are [[portacaval shunt]], [[peritoneovenous shunt]], and the [[transjugular intrahepatic portosystemic shunt]] (TIPS). However, none of these shunts has been shown to extend life expectancy, and are considered to be bridges to [[liver transplantation]].
A [[meta-analysis]] of [[randomized controlled trials]] by the international [[Cochrane Collaboration]] concluded that "TIPS was more effective at removing ascites as compared with paracentesis...however, TIPS patients develop hepatic encephalopathy significantly more often"<ref name="pmid17054221">{{cite journal |author=Saab S, Nieto JM, Lewis SK, Runyon BA |title=TIPS versus paracentesis for cirrhotic patients with refractory ascites |journal=Cochrane database of systematic reviews (Online) |volume= |issue=4 |pages=CD004889 |year=2006 |pmid=17054221 |doi=10.1002/14651858.CD004889.pub2}}</ref>


==Complications==
==Complications==
Line 82: Line 105:


== External links ==
== External links ==
National Institutes of Health [http://www.nlm.nih.gov/medlineplus/ency/article/000286.htm]
National Institutes of Health [http://www.nlm.nih.gov/medlineplus/ency/article/000286.htm][[Category:Suggestion Bot Tag]]

Latest revision as of 11:00, 13 July 2024

This article is developing and not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.

Ascites, also called hydroperitoneum or dropsy of the peritoneum, is the accumulation of serous fluids in the space between the tissues and organs of the abdominal (peritoneal) cavity. It can be a sign of serious health problems. It is often associated with cirrhosis or hepatitis, but may occur due to constrictive pericarditis, congestive heart failure, liver and ovarian cancer, pancreatitis, nephrotic syndrome, protein-losing enteropathy or portal vein thrombosis. The fluids can build up enough to cause pain and shortness of breath due to pressure on the diaphram.[1]

Classification

The Serum-ascities albumin gradient (SAAG) is probably a better discriminant than older measures (transudate versus exudate) for classifying ascites.[2]A high gradient (> 1.1 g/dL) indicates the ascites is due to portal hypertension. A low gradient (< 1.1 g/dL) indicates ascites of non-portal hypertensive etiology.

Causes of high SAAG ("transudate") are:[3]

Causes of low SAAG ("exudate") are:

Mixed causes

Among patients with cirrhosis, 5%[2] will have an additional etiology present. The most common second etiologies are spontaneous bacterial peritonitis, tuberculous peritonitis, and malignancy.[2] Among patients who have malignancy, most have abnormal imaging.[4]

Diagnosis

Physical examination

Physical examination findings have been systematically reviewed by the Rational Clinical Examination.[5][6]

Physical findings for ascites[5][6]
  Likelihood ratio+ Likelihood ratio-
Bulging flanks 1.8 0.48
Fluid wave 6.0 0.4
Peripheral edema 3.8 0.17

Ascitic fluid analysis

Some experts recommend paracentesis on all patients with new ascites.[7] Ascitic fluid analysis has been systematically reviewed by the Rational Clinical Examination[8]

The serum-ascites albumin gradient (SAAG) is usually above 1.1 g/dl; however, even lower values usually are due to portal hypertension.[4]

Testing for tuberculosis

Among patients with ascites, some patients will have underlying tuberculosis.[2] will have an additional etiology present. The most common second etiologies are spontaneous bacterial peritonitis, tuberculous peritonitis, and malignancy.[2] Some of these patients will have a positive purified protein derivative (PPD) test.

Imaging

Among patients with ascites, some patients will have underlying malignancy.[2] will have an additional etiology present. The most common second etiologies are spontaneous bacterial peritonitis, tuberculous peritonitis, and malignancy.[2] Most patients with malignancy will have abnormal imaging.[4]

Treatment

In patients with mild ascites, therapy is usually as an outpatient. The goal is weight loss of no more than 1.0 kg/day for patients with both ascites and peripheral edema and no more than 0.5 kg/day for patients with ascites alone.[9] In those with severe ascites causing a tense abdomen, hospitalization is generally necessary for paracentesis.[10][11]

Salt restriction

Salt restriction is the initial treatment, which allows diuresis (production of urine) since the patient now has more fluid than salt concentration. Salt restriction is effective in about 15% of patients.[12]

Diuretics

Since salt restriction is important in treatment, and aldosterone is one of the hormones that acts to increase salt retention, a medication that counteracts aldosterone should be beneficial. Spironolactone (or other distal-tubule diuretics such as triamterene or amiloride) block the aldosterone receptor in the collecting tubule. Their benefit was shown in a randomized controlled trial.[13]

Diuretics for ascites should be dosed once per day.[14] Generally, the starting dose is oral spironolactone 100 mg/day (max 400 mg/day). 40% of patients will respond to spironolactone.[12] For nonresponders, a loop diuretic may also be added and generally, furosemide is added at a dose of 40 mg/day (max 160 mg/day), or alternatively (bumetanide or torasemide). The ratio of 100:40 reduces risks of potassium imbalance.[14] Serum potassium level and renal function should be monitored closely while on these medications.[7]

A preliminary randomized controlled trial suggests that hypertonic saline solution combined with high-dose furosemide may be an effective alternative to repeated paracentesis for hospitalized patients.[15]

Monitoring diuresis

Diuresis can be monitored by weighing the patient daily. The goal is weight loss of no more than 1.0 kg/day for patients with both ascites and peripheral edema and no more than 0.5 kg/day for patients with ascites alone.[9] If daily weights cannot be obtained, diuretics can also be guided by the urinary sodium concentration. Dosage is increased until a negative sodium balance occurs.[14] A random urine sodium-to-potassium ratio of > 1 is 90% sensitive in predicting negative balance (> 78-mmol/day sodium excretion).[16]

Diuretic resistance

Diuretic resistance can be predicted by giving 80 mg intravenous furosemide after 3 days without diuretics and on an 80 mEq sodium/day diet. The urinary sodium excretion over 8 hours < 50 mEq/8 hours predicts resistance.[17]

Water restriction

Water restriction is needed if hyponatremia < 130 mmol per liter develops.[7]

Paracentesis

In those with severe (tense) ascites, therapeutic paracentesis may be needed in addition to medical treatments listed above.[10][11] As this may deplete serum albumin levels in the blood, albumin is generally administered intravenously in proportion to the amount of ascites removed.

Shunting

In patients with resistant ascites, shunts mayhelp. Options are portacaval shunt, peritoneovenous shunt, and the transjugular intrahepatic portosystemic shunt (TIPSS). However, none of these shunts has been shown to extend life expectancy.

Peritoneovenous shunt can speed resolution of ascites and delay its recurrence.[18] PV shunt has a restricted role, in part due to a 40% rate of obstruction over one year.[19]

TIPSS was better than peritoneovenous shunt in a randomized controlled trial.[20]

Liver transplantation

Ascites that is refractory to medical therapy is considered an indication for liver transplantation. In the United States, the MELD Score (online calculator)[21] is used to prioritize patients for transplantation.

Complications

Spontaneous bacterial peritonitis

For more information, see: Spontaneous bacterial peritonitis.


References

  1. Anonymous. Ascites. National Library of Medicine
  2. 2.0 2.1 2.2 2.3 2.4 2.5 2.6 Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, McHutchison JG (1992). "The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites.". Ann Intern Med 117 (3): 215-20. PMID 1616215.
  3. Warrell, D. A. (2003). Oxford textbook of medicine. Oxford: Oxford University Press. ISBN 0-19-262922-0. 
  4. 4.0 4.1 4.2 Khandwalla HE, Fasakin Y, El-Serag HB (2009). "The utility of evaluating low serum albumin gradient ascites in patients with cirrhosis.". Am J Gastroenterol 104 (6): 1401-5. DOI:10.1038/ajg.2009.117. PMID 19491852. Research Blogging.
  5. 5.0 5.1 Williams JW, Simel DL (May 1992). "The rational clinical examination. Does this patient have ascites? How to divine fluid in the abdomen". JAMA 267 (19): 2645–8. PMID 1573754[e]
  6. 6.0 6.1 Drummond Rennie; David Simel; Keitz, Sheri A. (2008). The rational clinical examination: evidence-based clinical diagnosis. New York: McGraw-Hill. ISBN 0-07-159030-7. 
  7. 7.0 7.1 7.2 Ginès P, Cárdenas A, Arroyo V, Rodés J (2004). "Management of cirrhosis and ascites.". N Engl J Med 350 (16): 1646-54. DOI:10.1056/NEJMra035021. PMID 15084697. Research Blogging.
  8. Wong CL, Holroyd-Leduc J, Thorpe KE, Straus SE (2008). "Does this patient have bacterial peritonitis or portal hypertension? How do I perform a paracentesis and analyze the results?". JAMA 299 (10): 1166-78. DOI:10.1001/jama.299.10.1166. PMID 18334692. Research Blogging.
  9. 9.0 9.1 Shear L, Ching S, Gabuzda GJ (1970). "Compartmentalization of ascites and edema in patients with hepatic cirrhosis". N. Engl. J. Med. 282 (25): 1391-6. PMID 4910836[e]
  10. 10.0 10.1 Ginés P, Arroyo V, Quintero E, et al (1987). "Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study". Gastroenterology 93 (2): 234-41. PMID 3297907[e]
  11. 11.0 11.1 Salerno F, Badalamenti S, Incerti P, et al (1987). "Repeated paracentesis and i.v. albumin infusion to treat 'tense' ascites in cirrhotic patients. A safe alternative therapy". J. Hepatol. 5 (1): 102-8. PMID 3655306[e]
  12. 12.0 12.1 Gatta A, Angeli P, Caregaro L, Menon F, Sacerdoti D, Merkel C (1991). "A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients". Hepatology 14 (2): 231-6. PMID 1860680[e]
  13. Fogel MR, Sawhney VK, Neal EA, Miller RG, Knauer CM, Gregory PB (1981). "Diuresis in the ascitic patient: a randomized controlled trial of three regimens". J. Clin. Gastroenterol. 3 Suppl 1: 73-80. PMID 7035545[e]
  14. 14.0 14.1 14.2 Runyon BA (1994). "Care of patients with ascites". N. Engl. J. Med. 330 (5): 337-42. PMID 8277955[e]
  15. Licata G, Tuttolomondo A, Licata A, Parrinello G, Di Raimondo D, Di Sciacca R et al. (2009). "Clinical Trial: High-dose furosemide plus small-volume hypertonic saline solutions vs. repeated paracentesis as treatment of refractory ascites.". Aliment Pharmacol Ther 30 (3): 227-35. DOI:10.1111/j.1365-2036.2009.04040.x. PMID 19438847. Research Blogging.
  16. Runyon BA, Heck M. Utility of 24-hour urine sodium collection and urine Na/K ratios in the management of patients with cirrhosis and ascites [abstract]. Hepatology. 1996;24:571A.
  17. Spahr L, Villeneuve JP, Tran HK, Pomier-Layrargues G (2001). "Furosemide-induced natriuresis as a test to identify cirrhotic patients with refractory ascites". Hepatology 33 (1): 28-31. DOI:10.1053/jhep.2001.20646. PMID 11124817. Research Blogging.
  18. Stanley MM, Ochi S, Lee KK, Nemchausky BA, Greenlee HB, Allen JI et al. (1989). "Peritoneovenous shunting as compared with medical treatment in patients with alcoholic cirrhosis and massive ascites. Veterans Administration Cooperative Study on Treatment of Alcoholic Cirrhosis with Ascites.". N Engl J Med 321 (24): 1632-8. PMID 2586565.
  19. Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G et al. (1996). "Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club.". Hepatology 23 (1): 164-76. DOI:10.1002/hep.510230122. PMID 8550036. Research Blogging.
  20. Rosemurgy AS, Zervos EE, Clark WC, Thometz DP, Black TJ, Zwiebel BR et al. (2004). "TIPS versus peritoneovenous shunt in the treatment of medically intractable ascites: a prospective randomized trial.". Ann Surg 239 (6): 883-9; discussion 889-91. PMID 15166968. PMC PMC1356297.
  21. Cosby RL, Yee B, Schrier RW (1989). "New classification with prognostic value in cirrhotic patients". Mineral and electrolyte metabolism 15 (5): 261-6. PMID 2682175[e]

External links

National Institutes of Health [1]